secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001516551-22-000016
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience amends arrangement agreement with Emerald Health Therapeutics, appoints new board and changes auditor
--------------------------------------------------------------------------------

- Filed amendment to Arrangement Agreement with Emerald Health Therapeutics waiving closing conditions and revising post-closing board.
- Dismissed Mayer Hoffman and engaged Friedman LLP as independent auditor for fiscal year 2022.
- Post-closing board includes Punit Dhillon, Bobby Rai, Praveen Tyle, Margaret Dalesandro, Keith Ward; management unchanged.
- Amendment removes requirement for waiver of change of control payments from Emerald Health Biotechnology Espana S.L.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000016/0001516551-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000016/skye-20220614.htm
  HTML page:      https://secwatch.observer/filing/0001516551-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer